Could a diabetes drug and an addiction pill curb alcohol cravings?
NCT ID NCT07249554
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial at Johns Hopkins will test whether combining semaglutide (a GLP-1 drug used for diabetes) with naltrexone (a medication for alcohol dependence) is safe and helps reduce alcohol use. About 45 adults with alcohol use disorder will take the combination or a placebo during a 4-week inpatient program. The study focuses on safety and early signs of effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide and naltrexone combination therapy
What this could lead to
If it works, this could point toward a new treatment option for alcohol use disorder that reduces cravings and drinking.
What could go wrong
This is a small, early Phase 2 trial with only 45 people, so results may not apply broadly. The combination may cause side effects or not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Ashley Addiction Treatment
Havre de Grace, Maryland, 21078, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••